CD40 antibodies with agonist activity have been developed and evaluated in clinic trials (26), and major tumor regressions have been observed in patients with breast cancer, pancreatic cancer, mesothelioma, and other tumors in combination with chemotherapy when CD40 antibodies are used with and without anti-CTLA4 mAb) therapy. Here, CTLA4 is linked to neoplasm.